QUOIN PHARMACEUTICALS LT-ADR (QNRX)

US74907L3006 - ADR

0.6  -0.02 (-3.26%)

After market: 0.595 -0.01 (-0.83%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (11/18/2024, 8:00:01 PM)

After market: 0.595 -0.01 (-0.83%)

0.6

-0.02 (-3.26%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-18.92%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.39M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

QNRX Daily chart

Company Profile

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Company Info

QUOIN PHARMACEUTICALS LT-ADR

23 Hata'as Street

Kfar Saba

P: 97299741444

CEO: Shai Yarkoni

Employees: 4

Website: https://quoinpharma.com/

QNRX News

News Image12 days ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant...

News Image18 days ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty...

News Image2 months ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Purchases Signal Leadership Confidence and Commitment to Company...

News Image3 months ago - InvestorPlaceQNRX Stock Earnings: Quoin Pharmaceuticals Beats EPS for Q2 2024

QNRX stock results show that Quoin Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.

News Image3 months ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton...

News Image3 months ago - Quoin Pharmaceuticals, Inc.Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New...

QNRX Twits

Here you can normally see the latest stock twits on QNRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example